share_log

HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50

HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50

HC Wainwright & Co.維持對Biora Therapeutics的買入,將目標價下調至50美元
Benzinga ·  2023/10/02 07:01

HC Wainwright & Co. analyst Joseph Pantginis maintains Biora Therapeutics (NASDAQ:BIOR) with a Buy and lowers the price target from $65 to $50.

HC Wainwright&Co.分析師約瑟夫·潘特吉尼斯維持Biora Treateutics(納斯達克:BIOR)的買入,並將目標價從65美元下調至50美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論